The Potential of Psychedelics for End of Life and Palliative Care

Yaden, David B.; Nayak, Sandeep; Gukasyan, Natalie; Anderson, B.; Griffiths, Roland R.

doi:10.1007/7854_2021_278

Cited by 13 publications

(12 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The new wave of psychedelic research has produced promising results, especially in treating hard-to-treat conditions ( Schlag, Aday, Salam, Neill, & Nutt, 2022 ) such as (treatment-resistant) substance use disorders, post-traumatic stress disorder, and depressive disorders. In addition, psychedelics have shown remarkable effects in assisting patients with existential end-of-life distress ( Kelmendi et al, 2016 ; Schimmers et al, 2022 ; Yaden et al, 2022 ).…”

Section: Recent Promising Resultsmentioning

confidence: 99%

Psychedelic-assisted therapy for people with gambling disorder?

Romero,

Czakó,

van den Brink

et al. 2024

JBA

View full text Add to dashboard Cite

Gambling disorder is a severe mental health and behavioural problem with harmful consequences, including financial, relationship and mental health problems. The present paper initiates discussion on the use of psychedelics combined with psychotherapeutic support as a potential treatment option for people living with a gambling disorder. Recent studies have shown promising results using psychedelic-assisted therapy (PAT) to treat anxiety, depression, post-traumatic stress disorder, and various substance use disorders. Considering the similarities in the underlying psychosocial and neurobiological mechanisms of gambling disorder and other addictive disorders, the authors suggest that psychedelic-assisted therapy could be effective in treating gambling disorder. The paper also underscores the need for further research into the viability and effectiveness of psychedelic-assisted therapy for gambling disorder.

show abstract

Section: Recent Promising Resultsmentioning

confidence: 99%

Psychedelic-assisted therapy for people with gambling disorder?

Romero,

Czakó,

van den Brink

et al. 2024

JBA

View full text Add to dashboard Cite

show abstract

“…Larger samples will also help addressing the important question of what treatments work for whom. It could well be that psychedelic therapy selectively works for specific patient groups, such as patients primarily coping with depression triggered through a life-threatening illness (Yaden et al, 2022), and current samples are not sufficiently large to find such effects: in a recently pooled moderation analysis of 17 ketamine studies including more than 800 patients however (Price, Kissel, et al, 2022), no consistent moderators were identified. This, in turn, highlights the need for more team-science, multicenter and multi-lab studies to conduct few high-powered, preregistered studies, rather than many underpowered open label studies that can fall prey to publication bias and other issues.…”

Section: Sample Sizementioning

confidence: 98%

History repeating: A roadmap to address common problems in psychedelic science

Elk¹,

Fried²

2023

Preprint

View full text Add to dashboard Cite

Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in a considerable increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that threaten the validity of core findings and raise doubt regarding clinical efficacy and safety. In this paper, we introduce the 10 most pressing challenges, grouped into easy, moderate, and hard problems. We show how these problems threaten internal validity (treatment effects are due to factors unrelated to the treatment), external validity (lack of generalizability), construct validity (unclear working mechanism) or statistical conclusion validity (conclusions do not follow from the data and methods). These problems tend to co-occur in psychedelic studies, strongly limiting conclusions that can be drawn about the safety and efficacy of psychedelic therapy. We provide a roadmap for tackling these challenges in the next decade of psychedelic science, and share a checklist that researchers, journalists, funders, policy makers, and other stakeholders can use to assess the quality of psychedelic science. Addressing today’s problems is necessary to find out whether the optimism regarding the potential of psychedelics has been warranted and to avoid history repeating itself.

show abstract

“…The results of these studies have been highly promising and suggest a forthcoming seismic shift in the psychiatric and psychotherapeutic treatment of a number of mental health concerns. Previously difficult to treat and debilitating afflictions such as post‐traumatic stress disorder (PTSD), major depressive disorder (MDD), severe somatic disorders, substance and alcohol use disorders (Siegel et al, 2021) as well as end‐of‐life anxiety (Yaden et al, 2022) seem to respond well to psychedelic‐assisted therapies. After decades of tireless labor of researchers, clinicians and advocates, there is now new hope for suffering individuals to benefit from psychedelic medicines in conjunction with psychotherapy (e.g., Greenway et al, 2020; Luoma et al, 2020; Schenberg, 2018).…”

Section: The Psychedelic Renaissance—a Brief Overviewmentioning

confidence: 99%

Chasing the Numinous: Hungry Ghosts in the Shadow of the Psychedelic Renaissance

Osterhold

Fernandes-Osterhold

2023

J Analytical Psychology

View full text Add to dashboard Cite

In recent years a renewed scientific, public and commercial interest in psychedelic medicines can be observed across the globe. As research findings have been generally promising, there is hope for new treatment possibilities for a number of difficult‐to‐treat mental health concerns. While honouring positive developments and therapeutic promise in relation to the medical use of psychedelics, this paper aims to shine a light on some underlying psycho‐cultural shadow dynamics in the unfolding psychedelic renaissance. This paper explores whether and how the multi‐layered collective fascination with psychedelics may yet be another symptom pointing towards a deeper psychological and spiritual malaise in the modern Western psyche as diagnosed by C. G. Jung. The question is posed whether the West’s feverish pursuit of psychedelic medicines—from individual consumption to entheogenic tourism, from capitalist commodification of medicines and treatments to the increasing number of ethical scandals and abuse through clinicians and self‐proclaimed shamans—is related to a Western cultural complex. As part of the discussion, the archetypal image of the Hungry Ghost, known across Asian cultural and religious traditions, is explored to better understand the aforementioned shadow phenomena and point towards mitigating possibilities.

show abstract

The Potential of Psychedelics for End of Life and Palliative Care

Cited by 13 publications

References 71 publications

Psychedelic-assisted therapy for people with gambling disorder?

Psychedelic-assisted therapy for people with gambling disorder?

History repeating: A roadmap to address common problems in psychedelic science

Chasing the Numinous: Hungry Ghosts in the Shadow of the Psychedelic Renaissance

Contact Info

Product

Resources

About